You can buy Ponaxen at the lowest price in the online pharmacy Nextgen.ooo . Ponatinib is a Bcr-Abl tyrosine kinase inhibitor that is particularly effective in the treatment of chronic myeloid leukemia with the T315I mutation. FDA approved on December 14, 2012. Ponatinib is indicated for the treatment of adult patients with chronic or blast phase chronic myeloid leukemia (CML) refractory to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome-positive acute lymphoblastic disease (Ph+ALL) refractory to prior tyrosine kinase inhibitor therapy.
 
Ponatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein, which is constitutively active and contributes to the progression of CML. This protein arises from the fusion gene of Bcr and Abl, the so-called Philadelphia chromosome. Ponatinib is unique in that it is particularly useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of mutant Abl and T315I kinases. The T315I mutation confers resistance to cells because it prevents other Bcr-Abl inhibitors from binding to Abl kinase. Other targets that ponatinib inhibits include members of the VEGFR, PDGFR, FGFR, EPH, and SRC kinase families, as well as KIT, RET, TIE2, and FLT3.